<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7202626</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0231217</article-id><article-id pub-id-type="publisher-id">PONE-D-19-35101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject><subj-group><subject>Reverse Transcriptase-Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject><subj-group><subject>Reverse Transcriptase-Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Asia</subject><subj-group><subject>Japan</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Metaanalysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Metaanalysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Geriatrics</subject></subj-group></subj-group></article-categories><title-group><article-title>Very high sensitivity of a rapid influenza diagnostic test in adults and elderly individuals within 48 hours of the onset of illness</article-title><alt-title alt-title-type="running-head">High sensitivity of a rapid influenza diagnostic test</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Seki</surname><given-names>Yuki</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oda</surname><given-names>Yukio</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4198-7414</contrib-id><name><surname>Sugaya</surname><given-names>Norio</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Internal Medicine, Keiyu Hospital, Yokohama, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Clinical Laboratory, Keiyu Hospital, Yokohama, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Pediatrics, Keiyu Hospital, Yokohama, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Dahiya</surname><given-names>Rajvir</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of California San Francisco, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>I have read the journal&#x02019;s policy and the authors of this manuscript have the following competing interests: within 36 months, Dr. Norio Sugaya has received speakers&#x02019; honoraria from Chugai, Shionogi, Daiichi Sankyo, Astellas, Merck, and Denka Seiken. Other authors have no competing interests regarding this study. TAUNS Laboratories, Inc. assisted for the testing the samples by RT-PCR in this study. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.</p></fn><corresp id="cor001">* E-mail: <email>sugaya-n@za2.so-net.ne.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>6</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>5</issue><elocation-id>e0231217</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Seki et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Seki et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0231217.pdf"/><abstract><p>During influenza epidemics, Japanese clinicians routinely perform rapid influenza diagnostic tests (RIDTs) in the examination of patients who have an influenza-like illness, and patients with positive test results, including otherwise healthy individuals, are treated with anti-influenza drugs. However, it was recently reported that the sensitivity of RIDTs was extremely low in adult patients. We examined the sensitivity and specificity of an RIDT that is widely used in Japan, ImunoAce Flu (TAUNS, Shizuoka, Japan), in comparison to reverse transcriptase polymerase chain reaction (RT-PCR). The sensitivity and specificity of the ImunoAce Flu test were 97.1% (95%CI: 93.8&#x02013;98.9) and 89.2% (95%CI: 84.1&#x02013;93.1), respectively. The ImunoAce Flu test is designed to not only detect influenza A or B, but also to detect H1N1pdm09 with the use of an additional test kit (Linjudge FluA/pdm). Its sensitivity and specificity for A/H1N1pdm09 were 97.6% (95%CI: 87.4&#x02013;99.9) and 92.6% (95%CI: 82.1&#x02013;97.9), respectively. Thus, by consecutively testing patients with the ImunoAce Flu test followed by the Linjudge FluA/pdm test, we are able to diagnose whether a patient has A/H1N1pdm09 or A/H3N2 infection within a short time. The reliability of rapid test results seems to be much higher in Japan than in other countries, because approximately 90% of influenza patients are tested and treated within 48 hours after the onset of illness, when the influenza viral load in the upper respiratory tract is high. From the Japanese experience, RIDTs are sufficiently sensitive and highly useful, if patients are tested within 48 hours after the onset of illness.</p></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data cannot be shared publicly because the data set includes patients&#x02019; personal information. Data are available from the Ethics Committee of Keiyu Hospita (<email>safety@keiyu-hospital.com</email> or FAX: 81-45-681-9665) or Dr. Norio Sugaya (<email>sugaya-n@za2.so-net.ne.jp</email>.) for researchers who meet the criteria for access to confidential data.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data cannot be shared publicly because the data set includes patients&#x02019; personal information. Data are available from the Ethics Committee of Keiyu Hospita (<email>safety@keiyu-hospital.com</email> or FAX: 81-45-681-9665) or Dr. Norio Sugaya (<email>sugaya-n@za2.so-net.ne.jp</email>.) for researchers who meet the criteria for access to confidential data.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>In Japan, more than 20 rapid influenza diagnostic tests (RIDTs) are marketed. These are considered core tools for determining whether to start treatment with anti-influenza drugs [<xref rid="pone.0231217.ref001" ref-type="bibr">1</xref>]. During influenza epidemics, Japanese clinicians routinely use RIDTs in the examination of patients with influenza-like illness (ILI), and patients with positive test results, including otherwise healthy individuals, are treated with anti-influenza drugs [<xref rid="pone.0231217.ref002" ref-type="bibr">2</xref>]. In Japan, approximately 20&#x02013;40 million RIDT kits are used every season [<xref rid="pone.0231217.ref003" ref-type="bibr">3</xref>], which costs approximately 200&#x02013;400 million US dollars per year.</p><p>A total of 4 neuraminidase inhibitors (NAIs) are currently used in hospitals and clinics in Japan. These include oseltamivir, zanamivir, the inhaled drug, laninamivir, and the intravenous drug, peramivir. Moreover, a new RNA polymerase inhibitor, baloxavir marboxil, was approved in 2018, and was widely used in the 2018&#x02013;19 season [<xref rid="pone.0231217.ref004" ref-type="bibr">4</xref>]. It was reported that over 5 million people were treated with baloxavir in Japan.</p><p>Even though over 20 million cases of infection were reported in Japan during the 2009 H1N1pdm pandemic, only 198 deaths were reported nationwide with no deaths of pregnant women [<xref rid="pone.0231217.ref005" ref-type="bibr">5</xref>]. The low mortality rate was attributable to the universal implementation of early treatment with NAIs based on universal testing with RIDTs [<xref rid="pone.0231217.ref001" ref-type="bibr">1</xref>].</p><p>The diagnosis of influenza based on clinical symptoms alone is difficult. In the US, antiviral treatment was infrequently prescribed for outpatients with influenza for whom therapy would have been most beneficial [<xref rid="pone.0231217.ref006" ref-type="bibr">6</xref>]. The potential benefits of a rapid and accurate diagnosis of influenza infection include prompt initiation of antiviral therapy [<xref rid="pone.0231217.ref007" ref-type="bibr">7</xref>], fewer ancillary diagnostic tests, fewer hospitalizations, prompt initiation of hospital infection control measures, and less unnecessary antibiotic therapy [<xref rid="pone.0231217.ref008" ref-type="bibr">8</xref>].</p><p>It was recently reported, based on a meta-analysis, that the sensitivity of RIDTs, antigen detection tests based on immunochromatography, was as low as 42.6% for influenza A and 33.2% for influenza B in adult patients [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>], although the specificity was reported to be over 99%. Another recent systematic review of RIDTs showed similar results [<xref rid="pone.0231217.ref010" ref-type="bibr">10</xref>], reporting that the sensitivity and specificity for influenza A+B in adults were 34.1% (95%CI: 14.0 to 54.1) and 99.2% (95%CI:98.2 to 100), respectively.</p><p>However, there was a serious problem in these reports, as they did not report the timing of sample collection for the RIDTs. The sensitivity of RIDTs is dependent on the viral load in the upper respiratory tract, and the viral titers of patients with influenza A virus infection in the upper respiratory tract peak during the first 1&#x02013;2 days after the onset of influenza infection, and decline to undetectable levels within a week [<xref rid="pone.0231217.ref011" ref-type="bibr">11</xref>]. The WHO Agenda for Public Health noted that the reliability of rapid tests in Japan seems to be higher than that in other countries, possibly because most patients are tested within 48 hours of the onset of illness, when influenza viral load in the upper respiratory tract is high [<xref rid="pone.0231217.ref001" ref-type="bibr">1</xref>].</p><p>The difference in clinical manifestations between A/H1N1pdm09 and A/H3N2 is very important in the clinical setting. For example, in young adults with H1N1pdm09, severe viral pneumonia sometimes develops as a complication [<xref rid="pone.0231217.ref012" ref-type="bibr">12</xref>], while elderly patients with A/H3N2 often develop bacterial pneumonia. Thus, it is highly beneficial for clinicians to distinguish between influenza A subtypes when they considering the treatment and prognosis of influenza A patients.</p><p>The purpose of this study was to examine the sensitivity and specificity of an RIDT that is widely used in Japan (ImunoAce Flu, TAUNS, Shizuoka, Japan), and to demonstrate its usefulness in the outpatient department of our hospital. ImunoAce Flu was reported to show high sensitivity and specificity in an <italic>in vitro</italic> study using viral cultures [<xref rid="pone.0231217.ref013" ref-type="bibr">13</xref>]. We compared its performance to the results of reverse transcriptase polymerase chain reaction (RT-PCR). ImunoAce Flu is designed to not only detect influenza A or B, but to also detect H1N1pdm09 with the use of an additional kit (Linjudge FluA/pdm; TAUNS, Shizuoka, Japan, for research use only). Thus, we also assessed the sensitivity and specificity of Linjudge FluA/pdm.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Clinical specimens</title><p>A total of 457 nasopharygeal swab specimens were collected from adults with ILI (upper respiratory symptoms and/or fever) at the outpatient department of Keiyu Hospital, Yokohama, Japan, in the 2018/2019 influenza season (December 2018 to March 2019). The study protocol was approved by the ethics committee of Keiyu Hospital (No.H27-24 in 2017). All subjects provided their informed consent to participate in our study. Nasopharyngeal swab specimens were tested with an ImunoAce Flu test kit.</p></sec><sec id="sec004"><title>ImunoAce Flu and Linjudge FluA/pdm</title><p>Samples collected by nasopharyngeal swabs were first tested by ImunoAce Flu [<xref rid="pone.0231217.ref014" ref-type="bibr">14</xref>], and the results were shown in 5 minutes. If patients were positive for influenza A, then the samples were further tested by Linjudge FluA/pdm [<xref rid="pone.0231217.ref015" ref-type="bibr">15</xref>]. This is an RIDT that can only detect A/H1N1pdm09, using a monoclonal antibody that is reactive against nucleoprotein (NP) of influenza A/H1N1pdm09, but not NP of A/H3N2 or seasonal A/H1N1. If a patient was found to be positive for influenza A by ImunoAce Flu and the Linjudge FluA/pdm test yielded a positive result, the patient was diagnosed with A/H1N1pdm09 infection (<xref ref-type="fig" rid="pone.0231217.g001">Fig 1</xref>). On the other hand, if the patient was found to be positive for influenza A by ImunoAce Flu, but the Linjudge FluA/pdm test yielded a negative result, the patient was diagnosed with influenza A other than A /H1N1pdm09 (<italic>i</italic>.<italic>e</italic>., A/H3N2 infection) (<xref ref-type="fig" rid="pone.0231217.g002">Fig 2</xref>). However, there is a possibility that the patient may have another kind of influenza A infection such as bird influenza, because ImunoAce Flu could detect A/H5N1 and A/H7N9 [<xref rid="pone.0231217.ref013" ref-type="bibr">13</xref>]. These tests were performed in the laboratory department of our hospital.</p><fig id="pone.0231217.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0231217.g001</object-id><label>Fig 1</label><caption><title>The patient was diagnosed with influenza A/H1N1pdm09 infection because she was found to be positive for influenza A by ImunoAce Flu (upper) and Linjudge FluA/pdm (lower).</title></caption><graphic xlink:href="pone.0231217.g001"/></fig><fig id="pone.0231217.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0231217.g002</object-id><label>Fig 2</label><caption><title>The patient was diagnosed with influenza A/H3N2 infection because he was positive for influenza A by ImunoAce Flu (upper) but negative by Linjudge FluA/pdm (lower).</title></caption><graphic xlink:href="pone.0231217.g002"/></fig></sec><sec id="sec005"><title>RT-PCR</title><p>The remaining samples were stored in a refrigerator in the laboratory department of Keiyu Hospital at -20&#x000b0;C. After the epidemic ceased in April 2019, they were sent to the laboratory of TAUNS (Shizuoka, Japan) and tested by RT-PCR. The laboratory that performed RT-PCR testing was not informed of the results of ImunoAce Flu and Linjudge FluA/pdm tests performed in Keiyu Hospital. Keiyu Hospital was informed of the RT-PCR results in June 2019. The results of the ImunoAce Flu and Linjudge FluA/pdm tests performed in Keiyu Hospital were then compared with the RT-PCR results.</p><p>RT-PCR samples were extracted using a QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) from 140 &#x003bc;L of remaining samples after performing the ImuoAce Flu test. Influenza A and B virus detection and the identification of influenza A/H1N1pdm09 and A/H3N2 subtypes was performed by real-time RT-PCR. Reverse transcription and amplification were performed using a One Step RT-PCR Kit Ver.2 (Takara Bio Inc., Shiga, Japan) and real-time RT-PCR was performed using a CFX96 Real-Time System (Bio-Rad Laboratories, Inc., California, USA). Testing was performed according to the Manual for the Diagnosis of Influenza Virus, Version 4 by the National Institute of Infectious Diseases [<xref rid="pone.0231217.ref016" ref-type="bibr">16</xref>].</p></sec><sec id="sec006"><title>Statistical analysis</title><p>EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for the R software program (the R Foundation for Statistical Computing, Vienna, Austria) was used to perform the statistical analyses. P values of &#x0003c;0.05 were considered to indicate statistical significance.</p></sec></sec><sec sec-type="results" id="sec007"><title>Results</title><p>In 2018&#x02013;19 influenza season in Japan, both influenza A subtypes (A/H1N1pdm09 and A/H3N2) were widely circulated [<xref rid="pone.0231217.ref017" ref-type="bibr">17</xref>]. The scale of the epidemic was the largest since the year 2000, resulting in more than 12 million cases of influenza A virus infection. In contrast, the influenza B epidemic was very small, and mostly involved the Victoria lineage. Thus, influenza B cases were excluded from our analysis.</p><p>A total of 457 nasopharygeal swab specimens were collected. Forty-seven specimens were excluded from the analysis for the following reasons: pediatric patient (n = 32), onset of ILI unknown (n = 7), and influenza B virus infection (n = 8). A total of 410 patients were eligible for inclusion in the analysis (male, n = 171; female, n = 239).</p><p>The median age of the patients in the study population was 57 years (inter-quartile-range [IQR]: 36&#x02013;78 years); 42.2% of the patients (173/410) were &#x02265;65 years of age, and the median age of the elderly patients was 80.0 years of age (IQR: 71&#x02013;87 years).</p><p>Most patients (89.8%: 368/410) visited the outpatient department of our hospital within 48 hours after the onset of illness and received an RIDT. Sixty percent (247/410) of the patients visited our hospital within 24 hours after the onset of illness, and received an RIDT.</p><p>The overall performance of ImunoAce Flu in comparison with RT-PCR is shown in <xref rid="pone.0231217.t001" ref-type="table">Table 1</xref>. ImunoAce Flu showed high sensitivity (97.1%) in the detection of influenza A virus (95%CI: 93.8&#x02013;98.9), but relatively low specificity (89.2%; 95%CI: 84.1&#x02013;93.1). When the subjects were limited to patients tested within 48 hours after the onset of illness, the sensitivity and specificity were 97.9% (95%CI: 94.7&#x02013;99.4) and 90.4% (95%CI: 85.1&#x02013;94.3), respectively (<xref rid="pone.0231217.t002" ref-type="table">Table 2</xref>).</p><table-wrap id="pone.0231217.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0231217.t001</object-id><label>Table 1</label><caption><title>Sensitivity and specificity of ImunoAce Flu according to age group.</title></caption><alternatives><graphic id="pone.0231217.t001g" xlink:href="pone.0231217.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">TP<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></th><th align="center" rowspan="1" colspan="1">FP<xref ref-type="table-fn" rid="t001fn002"><sup>b</sup></xref></th><th align="center" rowspan="1" colspan="1">TN<xref ref-type="table-fn" rid="t001fn003"><sup>c</sup></xref></th><th align="center" rowspan="1" colspan="1">FN<xref ref-type="table-fn" rid="t001fn004"><sup>d</sup></xref></th><th align="center" rowspan="1" colspan="1">Number of Patients</th><th align="center" rowspan="1" colspan="1">% Sensitivity</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">% Specificity</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">PPV<xref ref-type="table-fn" rid="t001fn005"><sup>e</sup></xref></th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">NPV<xref ref-type="table-fn" rid="t001fn006"><sup>f</sup></xref></th><th align="center" rowspan="1" colspan="1">95%CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">201</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">181</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">410</td><td align="char" char="." rowspan="1" colspan="1">97.1</td><td align="center" rowspan="1" colspan="1">93.8&#x02013;98.9</td><td align="center" rowspan="1" colspan="1">89.2</td><td align="center" rowspan="1" colspan="1">84.1&#x02013;93.1</td><td align="center" rowspan="1" colspan="1">90.1</td><td align="center" rowspan="1" colspan="1">85.4&#x02013;93.7</td><td align="char" char="." rowspan="1" colspan="1">96.8</td><td align="center" rowspan="1" colspan="1">93.1&#x02013;98.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;65years</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">237</td><td align="char" char="." rowspan="1" colspan="1">97.5</td><td align="center" rowspan="1" colspan="1">92.9&#x02013;99.5</td><td align="center" rowspan="1" colspan="1">86.3</td><td align="center" rowspan="1" colspan="1">78.7&#x02013;92</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">81.2&#x02013;93</td><td align="char" char="." rowspan="1" colspan="1">97.1</td><td align="center" rowspan="1" colspan="1">91.8&#x02013;99.4</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x02265;65years</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">173</td><td align="char" char="." rowspan="1" colspan="1">96.6</td><td align="center" rowspan="1" colspan="1">90.3&#x02013;99.3</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">85.4&#x02013;97.4</td><td align="center" rowspan="1" colspan="1">93.3</td><td align="center" rowspan="1" colspan="1">86.1&#x02013;97.5</td><td align="char" char="." rowspan="1" colspan="1">96.4</td><td align="center" rowspan="1" colspan="1">89.8&#x02013;99.2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><sup>a,</sup> true positive;</p></fn><fn id="t001fn002"><p><sup>b,</sup> false positive;</p></fn><fn id="t001fn003"><p><sup>c,</sup> true negative;</p></fn><fn id="t001fn004"><p><sup>d,</sup> false negative;</p></fn><fn id="t001fn005"><p><sup>e,</sup> positive predictive value;</p></fn><fn id="t001fn006"><p><sup>f,</sup> negative predictive value.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0231217.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0231217.t002</object-id><label>Table 2</label><caption><title>Accumulated sensitivity and specificity of ImunoAce Flu.</title></caption><alternatives><graphic id="pone.0231217.t002g" xlink:href="pone.0231217.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Hours after onset</th><th align="center" rowspan="1" colspan="1">TP<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref></th><th align="center" rowspan="1" colspan="1">FP<xref ref-type="table-fn" rid="t002fn002"><sup>b</sup></xref></th><th align="center" rowspan="1" colspan="1">TN<xref ref-type="table-fn" rid="t002fn003"><sup>c</sup></xref></th><th align="center" rowspan="1" colspan="1">FN<xref ref-type="table-fn" rid="t002fn004"><sup>d</sup></xref></th><th align="center" rowspan="1" colspan="1">Number of Patients</th><th align="center" rowspan="1" colspan="1">% Sensitivity</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">% Specificity</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">PPV<xref ref-type="table-fn" rid="t002fn005"><sup>e</sup></xref></th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">NPV<xref ref-type="table-fn" rid="t002fn006"><sup>f</sup></xref></th><th align="center" rowspan="1" colspan="1">95%CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">&#x02266;12</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">85.8&#x02013;100</td><td align="center" rowspan="1" colspan="1">97.8</td><td align="center" rowspan="1" colspan="1">88.5&#x02013;99.9</td><td align="char" char="." rowspan="1" colspan="1">97.3</td><td align="center" rowspan="1" colspan="1">85.8&#x02013;99.9</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">88.5&#x02013;100</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x02266;24</td><td align="center" rowspan="1" colspan="1">158</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">152</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">329</td><td align="center" rowspan="1" colspan="1">97.5</td><td align="center" rowspan="1" colspan="1">93.8&#x02013;99.3</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">85.6&#x02013;94.9</td><td align="char" char="." rowspan="1" colspan="1">91.3</td><td align="center" rowspan="1" colspan="1">86.1&#x02013;95.1</td><td align="center" rowspan="1" colspan="1">97.4</td><td align="center" rowspan="1" colspan="1">93.6&#x02013;99.3</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x02266;48</td><td align="center" rowspan="1" colspan="1">186</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">161</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">368</td><td align="center" rowspan="1" colspan="1">97.9</td><td align="center" rowspan="1" colspan="1">94.7&#x02013;99.4</td><td align="center" rowspan="1" colspan="1">90.4</td><td align="center" rowspan="1" colspan="1">85.1&#x02013;94.3</td><td align="char" char="." rowspan="1" colspan="1">91.6</td><td align="center" rowspan="1" colspan="1">86.9&#x02013;95</td><td align="center" rowspan="1" colspan="1">97.6</td><td align="center" rowspan="1" colspan="1">93.9&#x02013;99.3</td></tr><tr><td align="center" rowspan="1" colspan="1">Total (&#x0003e;48)</td><td align="center" rowspan="1" colspan="1">201</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">181</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">410</td><td align="center" rowspan="1" colspan="1">97.1</td><td align="center" rowspan="1" colspan="1">93.8&#x02013;98.9</td><td align="center" rowspan="1" colspan="1">89.2</td><td align="center" rowspan="1" colspan="1">84.1&#x02013;93.1</td><td align="char" char="." rowspan="1" colspan="1">90.1</td><td align="center" rowspan="1" colspan="1">85.4&#x02013;93.7</td><td align="center" rowspan="1" colspan="1">96.8</td><td align="center" rowspan="1" colspan="1">93.1&#x02013;98.8</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><sup>a,</sup> true positive;</p></fn><fn id="t002fn002"><p><sup>b,</sup> false positive;</p></fn><fn id="t002fn003"><p><sup>c,</sup> true negative;</p></fn><fn id="t002fn004"><p><sup>d,</sup> false negative;</p></fn><fn id="t002fn005"><p><sup>e,</sup> positive predictive value;</p></fn><fn id="t002fn006"><p><sup>f,</sup> negative predictive value.</p></fn></table-wrap-foot></table-wrap><p>Among elderly patients of &#x02265;65 years of age, the sensitivity and specificity of ImunoAce Flu for influenza A virus were 96.6% (95%CI: 90.3&#x02013;99.3) and 93% (95%CI: 85.4&#x02013;97.4), respectively. In contrast, in adults of &#x0003c;65 years of age, the sensitivity and specificity were 97.5% (95%CI: 92.9&#x02013;99.5) and 86.3% (95%CI: 78.7&#x02013;92.0), respectively (<xref rid="pone.0231217.t001" ref-type="table">Table 1</xref>). However, there was no significant difference in specificity between the &#x02265;65 years and &#x0003c;65 years age groups (p = 0.757).</p><p><xref rid="pone.0231217.t002" ref-type="table">Table 2</xref> showed the accumulated sensitivity and specificity of ImunoAce Flu from within 12 hours after the onset of illness to &#x0003e;48 hours after the onset of illness. Within 48 hours after the onset of illness, the sensitivity and specificity were 97.9% (95%CI: 94.7&#x02013;99.4) and 90.4% (95%CI: 85.1&#x02013;94.3), respectively (n = 368). At more than 48 hours after the onset of illness, the sensitivity of the RIDT did not decrease, remaining at 97.1%; however, there was a slight decrease in specificity, which fell to 89.3%.</p><p>Within 12 hours after the onset of illness, the sensitivity and specificity were 100% and 97.8%, respectively (n = 82). Although the sensitivity did not decrease within 48 hours, the specificity gradually decreased with time, as follows: within 12 hours, 97.8%; 13&#x02013;24 hours, 88.8%; 25&#x02013;48 hours, 81.8% (<xref rid="pone.0231217.t003" ref-type="table">Table 3</xref><bold>)</bold>. After 48 hours, both the sensitivity and specificity decreased. However, there was no statistically significant difference in the sensitivity and specificity between the patients tested within 12 hours after the onset of illness and those tested at more than 48 hours after the onset of illness.</p><table-wrap id="pone.0231217.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0231217.t003</object-id><label>Table 3</label><caption><title>Sensitivity and specificity of ImunoAce Flu according to time after the onset of illness.</title></caption><alternatives><graphic id="pone.0231217.t003g" xlink:href="pone.0231217.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Hours after onset</th><th align="center" rowspan="1" colspan="1">TP<xref ref-type="table-fn" rid="t003fn001"><sup>a</sup></xref></th><th align="center" rowspan="1" colspan="1">FP<xref ref-type="table-fn" rid="t003fn002"><sup>b</sup></xref></th><th align="center" rowspan="1" colspan="1">TN<xref ref-type="table-fn" rid="t003fn003"><sup>c</sup></xref></th><th align="center" rowspan="1" colspan="1">FN<xref ref-type="table-fn" rid="t003fn004"><sup>d</sup></xref></th><th align="center" rowspan="1" colspan="1">Number of Patients</th><th align="center" rowspan="1" colspan="1">% Sensitivity</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">% Specificity</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">PPV<xref ref-type="table-fn" rid="t003fn005"><sup>e</sup></xref></th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">NPV<xref ref-type="table-fn" rid="t003fn006"><sup>f</sup></xref></th><th align="center" rowspan="1" colspan="1">95%CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">&#x02266;12</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">85.8&#x02013;100</td><td align="center" rowspan="1" colspan="1">97.8</td><td align="center" rowspan="1" colspan="1">88.5&#x02013;99.9</td><td align="center" rowspan="1" colspan="1">97.3</td><td align="center" rowspan="1" colspan="1">85.8&#x02013;99.9</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">88.5&#x02013;100</td></tr><tr><td align="center" rowspan="1" colspan="1">13&#x02013;24</td><td align="center" rowspan="1" colspan="1">122</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">107</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">247</td><td align="center" rowspan="1" colspan="1">96.8</td><td align="center" rowspan="1" colspan="1">92.1&#x02013;99.1</td><td align="center" rowspan="1" colspan="1">88.4</td><td align="center" rowspan="1" colspan="1">81.3&#x02013;93.5</td><td align="center" rowspan="1" colspan="1">89.7</td><td align="center" rowspan="1" colspan="1">83.3&#x02013;94.3</td><td align="center" rowspan="1" colspan="1">96.4</td><td align="center" rowspan="1" colspan="1">91.0&#x02013;99.0</td></tr><tr><td align="center" rowspan="1" colspan="1">25&#x02013;48</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">82.2&#x02013;100</td><td align="center" rowspan="1" colspan="1">81.8</td><td align="center" rowspan="1" colspan="1">48.2&#x02013;97.7</td><td align="center" rowspan="1" colspan="1">93.3</td><td align="center" rowspan="1" colspan="1">77.9&#x02013;99.2</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">55.5&#x02013;100</td></tr><tr><td align="center" rowspan="1" colspan="1">49-</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">88.2</td><td align="center" rowspan="1" colspan="1">63.6&#x02013;98.5</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">59.3&#x02013;93.2</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">91.3</td><td align="center" rowspan="1" colspan="1">90.9</td><td align="center" rowspan="1" colspan="1">70.8&#x02013;98.9</td></tr><tr><td align="center" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">201</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">181</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">410</td><td align="center" rowspan="1" colspan="1">97.1</td><td align="center" rowspan="1" colspan="1">93.8&#x02013;98.9</td><td align="center" rowspan="1" colspan="1">89.2</td><td align="center" rowspan="1" colspan="1">84.1&#x02013;93.1</td><td align="center" rowspan="1" colspan="1">90.1</td><td align="center" rowspan="1" colspan="1">85.4&#x02013;93.7</td><td align="center" rowspan="1" colspan="1">96.8</td><td align="center" rowspan="1" colspan="1">93.1&#x02013;98.8</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><sup>a,</sup> true positive;</p></fn><fn id="t003fn002"><p><sup>b,</sup> false positive;</p></fn><fn id="t003fn003"><p><sup>c,</sup> true negative;</p></fn><fn id="t003fn004"><p><sup>d,</sup> false negative;</p></fn><fn id="t003fn005"><p><sup>e,</sup> positive predictive value;</p></fn><fn id="t003fn006"><p><sup>f,</sup> negative predictive value.</p></fn></table-wrap-foot></table-wrap><p>We additionally performed the Linjudge FluA/pdm test for patients who were found to be positive for influenza A by ImunoAce Flu (n = 96) (<xref rid="pone.0231217.t004" ref-type="table">Table 4</xref>). Six of the 96 cases that were found to be positive for influenza A by ImunoAce Flu were found to be false-positives by RT-PCR. Thus, these were excluded from the analysis. Among the patients in whom influenza A positivity was confirmed by RT-PCR (n = 90), 42 patients were found to be positive for H1N1pdm09 by Linjudge FluA/pdm. RT-PCR revealed that one of these cases was H3N2 virus infection. Thus, the sensitivity of Linjudge FluA/pdm for H1N1pdm was 97.6% (41/42, 95%CI: 87.4&#x02013;99.9).</p><table-wrap id="pone.0231217.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0231217.t004</object-id><label>Table 4</label><caption><title>Sensitivity and specificity of Linjudge FluA/pdm.</title></caption><alternatives><graphic id="pone.0231217.t004g" xlink:href="pone.0231217.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Influenza A</th><th align="center" rowspan="1" colspan="1">Positive</th><th align="center" rowspan="1" colspan="1">Negative</th><th align="center" rowspan="1" colspan="1">TP<xref ref-type="table-fn" rid="t004fn001"><sup>a</sup></xref></th><th align="center" rowspan="1" colspan="1">FP<xref ref-type="table-fn" rid="t004fn002"><sup>b</sup></xref></th><th align="center" rowspan="1" colspan="1">TN<xref ref-type="table-fn" rid="t004fn003"><sup>c</sup></xref></th><th align="center" rowspan="1" colspan="1">FN<xref ref-type="table-fn" rid="t004fn004"><sup>d</sup></xref></th><th align="center" rowspan="1" colspan="1">% Sensitivity</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">% Specificity</th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">PPV<xref ref-type="table-fn" rid="t004fn005"><sup>e</sup></xref></th><th align="center" rowspan="1" colspan="1">95%CI</th><th align="center" rowspan="1" colspan="1">NPV<xref ref-type="table-fn" rid="t004fn006"><sup>f</sup></xref></th><th align="center" rowspan="1" colspan="1">95%CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">96<xref ref-type="table-fn" rid="t004fn007"><sup>1)</sup></xref></td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">50*</td><td align="center" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">97.6</td><td align="center" rowspan="1" colspan="1">87.4&#x02013;99.9</td><td align="char" char="." rowspan="1" colspan="1">92.6</td><td align="center" rowspan="1" colspan="1">82.1&#x02013;97.9</td><td align="char" char="." rowspan="1" colspan="1">91.1</td><td align="center" rowspan="1" colspan="1">78.8&#x02013;97.5</td><td align="center" rowspan="1" colspan="1">98</td><td align="center" rowspan="1" colspan="1">89.6&#x02013;1.00</td></tr><tr><td align="center" rowspan="1" colspan="1">90<xref ref-type="table-fn" rid="t004fn008"><sup>2)</sup></xref></td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">97.6</td><td align="center" rowspan="1" colspan="1">87.4&#x02013;99.9</td><td align="char" char="." rowspan="1" colspan="1">91.7</td><td align="center" rowspan="1" colspan="1">80&#x02013;97.7</td><td align="char" char="." rowspan="1" colspan="1">91.1</td><td align="center" rowspan="1" colspan="1">78.8&#x02013;97.5</td><td align="center" rowspan="1" colspan="1">97.8</td><td align="center" rowspan="1" colspan="1">88.2&#x02013;99.9</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p><sup>a,</sup> true positive;</p></fn><fn id="t004fn002"><p><sup>b,</sup> false positive;</p></fn><fn id="t004fn003"><p><sup>c,</sup> true negative;</p></fn><fn id="t004fn004"><p><sup>d,</sup> false negative;</p></fn><fn id="t004fn005"><p><sup>e,</sup> positive predictive value;</p></fn><fn id="t004fn006"><p><sup>f,</sup> negative predictive value.</p></fn><fn id="t004fn007"><p><sup>1)</sup> influenza A by ImunoAce Flu;</p></fn><fn id="t004fn008"><p><sup>2)</sup>, influenza A comfirmed by RT-PCR.</p></fn></table-wrap-foot></table-wrap><p>In contrast, among the 90 patients who were found to be positive for influenza A by ImunoAce Flu, 44 patients were found to be negative by Linjudge FluA/pdm and were confirmed to have A/H3N2 infection by RT-PCR. Moreover, 4 patients who were found to be positive by Linjudge FluA/pdm were diagnosed with H3N2 by RT-PCR. In total, 48 patients, including 4 patients for whom Linjudge FluA/pdm yielded a false-positive for H1N1pdm09, were diagnosed with H3N2 virus infection by RT-PCR. Thus, the specificity of Linjudge FluA/pdm was 91.7% (44/48, 95%CI: 80.0&#x02013;97.7).</p><p>Moreover, 6 cases in which ImunoAce Flu yielded a false-positive result were found to be negative by Linjudge FluA/pdm. Thus, if the 6 cases were included in the analysis, the specificity of Linjudge FluA/pdm would be 92.6% (50/54, 95%CI: 82.1&#x02013;97.9).</p></sec><sec sec-type="conclusions" id="sec008"><title>Discussion</title><p>Based on a meta-analysis, RIDTs (<italic>i</italic>.<italic>e</italic>., antigen detection tests based on the immunochromatography) were reported to show low sensitivity (42.6%; 95%CI: 34.8&#x02013;50.9) for influenza A in adult patients [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>]. In contrast, an RIDT used in Japan, ImunoAce Flu, showed much 97.1% sensitivity in the detection of influenza A viruses (95%CI: 93.8&#x02013;98.9) in adult patients (<xref rid="pone.0231217.t001" ref-type="table">Table 1</xref>). The performance of RIDTs used in Japan might be higher than those reported in the meta-analysis [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>]. In the same meta-analysis, it was also reported that RIDTs that utilize analyzer devices showed higher sensitivity in the detection of influenza viral antigens than RIDTs without analyzer devices. For example, the BD Veritor System, classified as &#x0201c;a digital immunoassay&#x0201d; in the meta-analysis report [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>], showed 83.0% sensitivity and 97.5% specificity, which was much higher in comparison to RIDTs without analyzer devices. Although the BD Veritor System is also used in Japan, this superiority is not recognized. The minimum viral titer required for a positive reaction for influenza A viruses using the BD Veritor System (10<sup>3</sup>&#x02212;10<sup>4</sup> TCID50 per 100 &#x003bc;l) was similar to that required by ImunoAce Flu [<xref rid="pone.0231217.ref013" ref-type="bibr">13</xref>].</p><p>The sensitivity of RIDT is dependent on the viral load in the upper respiratory tract [<xref rid="pone.0231217.ref001" ref-type="bibr">1</xref>]. However, the timing at which samples were collected was not described in the recent meta-analyses that reported the low sensitivity of RIDTs [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0231217.ref010" ref-type="bibr">10</xref>]. The Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) emphasize that clinicians should collect upper respiratory tract specimens as soon as possible, preferably within 4 days after the onset of symptoms [<xref rid="pone.0231217.ref018" ref-type="bibr">18</xref>]. Accordingly, we believe that the recent reports [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0231217.ref010" ref-type="bibr">10</xref>] included the results of many patients tested with RIDT kits at 4&#x02013;5 days after the onset of illness. In contrast, in our study, most patients (89.8%) visited the outpatient department of our hospital within 48 hours after the onset of illness. Infectious influenza virus levels in the upper respiratory tract of persons with uncomplicated influenza peak during the first 1&#x02013;2 days after illness onset, and decline to undetectable levels within a week [<xref rid="pone.0231217.ref018" ref-type="bibr">18</xref>]. In Japan, the early diagnosis and treatment of influenza are now standard practice [<xref rid="pone.0231217.ref002" ref-type="bibr">2</xref>].</p><p>Another important factor related to the high sensitivity of RIDTs in Japan was the measure used to collect samples for RIDTs. In our study, nasopharyngeal swabs were used as samples for all tests. In contrast, in the meta-analysis report, nasopharyngeal swabs or aspirate were used as test samples for &#x0003c;44% of tests [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>]. The IDSA guidelines emphasize that nasopharyngeal specimens should be collected rather than other upper respiratory tract specimens in order to increase the detection of influenza [<xref rid="pone.0231217.ref018" ref-type="bibr">18</xref>].</p><p>ImunoAce Flu showed 89.2% specificity (95%CI: 84.1&#x02013;93.1), which is relatively low (<xref rid="pone.0231217.t001" ref-type="table">Table 1</xref>). When the study population was limited to patients who were tested within 48 hours after the onset of illness, the specificity was 90.4% (95%CI: 85.1&#x02013;94.3) (<xref rid="pone.0231217.t002" ref-type="table">Table 2</xref>). In contrast, the specificity was &#x0003e;99.9% (95%CI: 99.4&#x02013;100) in the meta-analysis report [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>]. The manuals for the other RIDT kits used in Japan report their sensitivity (88%&#x02013;100%) and specificity (94%&#x02013;100%) [<xref rid="pone.0231217.ref019" ref-type="bibr">19</xref>]. The low specificity in the present study may be attributable to the characteristics of the monoclonal antibody used in the ImunoAce Flu test kit.</p><p>The performance of RIDTs is usually discussed based on the clinical data in children. The performance is significantly better in children [<xref rid="pone.0231217.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0231217.ref021" ref-type="bibr">21</xref>], because age is inversely associated with viral load. This explains the better test results in children, and leads to some doubt regarding the diagnostic value of RIDTs in elderly persons [<xref rid="pone.0231217.ref022" ref-type="bibr">22</xref>]. In one meta-analysis report [<xref rid="pone.0231217.ref010" ref-type="bibr">10</xref>], the diagnostic test accuracy for influenza was significantly decreased in adults in comparison to children or a mixed population.</p><p>However, in our study, the sensitivity of ImunoAce Flu was sufficiently high in adults, especially in elderly individuals of &#x0003e;65 years of age (<xref rid="pone.0231217.t001" ref-type="table">Table 1</xref>). Another Japanese report showed that the sensitivity did not differ between children and adults [<xref rid="pone.0231217.ref023" ref-type="bibr">23</xref>]. In that report, the sensitivity of a Japanese RIDT, Prolast Flu AB (Mitsubishi Chemical Medience Corporation, Japan) for H1N1pdm09 was as high as 80&#x02013;90% during the H1N1 pandemic of 2009. In contrast, RIDTs were reported to show low sensitivity in the detection of influenza A/H1N1pdm09 virus (40&#x02013;69%) in the H1N1 pandemic of 2009 in the US [<xref rid="pone.0231217.ref024" ref-type="bibr">24</xref>].</p><p>The IDSA guidelines recommend that clinicians use rapid molecular assays, that is, nucleic acid amplification tests (NAAT), rather than RIDTs for the testing of outpatients in order to improve the detection of influenza virus infection [<xref rid="pone.0231217.ref018" ref-type="bibr">18</xref>]. According to the meta-analysis [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>], the pooled sensitivity and specificity of rapid molecular tests for influenza A were 87.4% (95%CI: 71.1&#x02013;95.6) and 99.0% (95%CI: 93.2&#x02013;99.5), respectively, in adults. The sensitivity and specificity of a rapid molecular test, ID NOW2 (Abott Diagnostics, USA), for influenza A were reported to be 95.9% (95%CI: 89.9&#x02013;98.9) and of 100% (95%CI: 98.1&#x02013;100), respectively [<xref rid="pone.0231217.ref025" ref-type="bibr">25</xref>], which was reported from Japan, and most patients&#x02014;mainly children&#x02014;were tested within 48 hours after the onset of illness. In our study, in which patients were tested within 48 hours after the onset of ILI, the sensitivity of ImunoAce Flu in the detection of influenza A was as high as the sensitivity of rapid molecular tests [<xref rid="pone.0231217.ref025" ref-type="bibr">25</xref>]. However, the specificity of ImunoAce Flu within 48 hours after the onset of illness was 90.4% (<xref rid="pone.0231217.t002" ref-type="table">Table 2</xref>), which was lower than the specificity of rapid molecular assays [<xref rid="pone.0231217.ref009" ref-type="bibr">9</xref>] [<xref rid="pone.0231217.ref025" ref-type="bibr">25</xref>]. Similarly, in a report from Japan [<xref rid="pone.0231217.ref025" ref-type="bibr">25</xref>], sensitivity and specificity of an RIDT, QUICKNAVI (Otsuka Pharmaceutical Co, Japan) were comparable to the sensitivity and specificity of a rapid molecular assay, ID NOW2. Based on the Japanese experience, RIDTs are sufficiently sensitive and highly useful if patients are tested within 48 hours after the onset of illness. Thus, in countries where an early diagnosis and treatment are possible, an RIDT is probably one of the most useful alternatives for diagnosing influenza. For example, in Israel, &#x0003e;50% of patients with ILI visited clinics at 0&#x02013;1 days after the onset of ILI [<xref rid="pone.0231217.ref026" ref-type="bibr">26</xref>].</p><p>The distinction of influenza A subtypes, A/H1N1pdm and A/H3N2, has been taken seriously because of characteristic clinical manifestations. Recently, however, it has become more important, mainly because of the lower effectiveness of the influenza vaccine against A/H3N2 [<xref rid="pone.0231217.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0231217.ref028" ref-type="bibr">28</xref>]. Moreover, resistance to a polymerase inhibitor, baloxavir marboxil, is frequently reported, especially in patients with influenza A/H3N2 [<xref rid="pone.0231217.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0231217.ref029" ref-type="bibr">29</xref>]. We could not distinguish between the influenza A subtypes by traditional RIDTs or rapid molecular assays, unless we used RT-PCR. However, with the combination of ImunoAce Flu and Linjudge FluA/pdm, distinction between influenza A subtypes becomes feasible.</p><p>Our study demonstrated the high sensitivity (97.6%; 95%CI: 87.4&#x02013;99.9) and specificity (92.6%; 95%CI: 82.1&#x02013;97.9) of Linjudge FluA/pdm in the detection of A/H1N1pdm09 (<xref rid="pone.0231217.t004" ref-type="table">Table 4</xref>). Thus, by testing patients consecutively with ImunoAce Flu then Linjudge FluA/pdm, we are able to diagnose whether patients had A/H1N1pdm09 infection or A/H3M2 infection within a short time. ImunoAce Flu takes up to 5 minutes to obtain results [<xref rid="pone.0231217.ref014" ref-type="bibr">14</xref>], while Linjudge FluA/pdm takes up to 15 minutes [<xref rid="pone.0231217.ref015" ref-type="bibr">15</xref>]; however, highly accurate results are usually obtained within a total of 10 minutes. Another RIDT kit that is capable of distinguishing between the influenza A subtypes had been on the market until several years ago, Clearline Influenza A/B/(H1N1) 2009 [<xref rid="pone.0231217.ref030" ref-type="bibr">30</xref>]; however, it has since been withdrawn due to unstable results. The combination of ImunoAce Flu and Linjudge FluA/pdm is highly useful for distinguishing between influenza A subtypes, in comparison to RT-PCR, although the sensitivity and specificity of the combination of tests is lower. Moreover, this combination of tests obtains results in much less time, and numerous samples can be tested at the same time. The most important point is its cost, which at approximately 10 US dollars per test, is much cheaper in comparison to RT-PCR.</p><p>The present study was associated with several limitations. In some severe influenza cases, including cases with viral pneumonia [<xref rid="pone.0231217.ref031" ref-type="bibr">31</xref>], the infectious titer in the upper respiratory tract is reported to be low. Thus, negative test results in such cases should probably be confirmed by further testing using RT-PCR or other molecular assays to improve the detection of influenza virus infection [<xref rid="pone.0231217.ref018" ref-type="bibr">18</xref>]. In the present study, we only analyzed the performance of ImunoAce Flu in the detection of influenza A virus infection.</p><p>In conclusion, based on the Japanese experience, RIDTs are sufficiently sensitive and highly useful for the detection of influenza A if patients are tested within 48 hours after the onset of illness.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0231217.ref001"><label>1</label><mixed-citation publication-type="other">WHO. WHO Public Health Research Agenda for Influenza, Background Document, Stream 4, 2018 [<ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/handle/10665/259887/WHO-WHE-IHM-GIP-2017.7-eng.pdf?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/259887/WHO-WHE-IHM-GIP-2017.7-eng.pdf?sequence=1</ext-link>.</mixed-citation></ref><ref id="pone.0231217.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Sugaya</surname><given-names>N</given-names></name>. <article-title>Widespread use of neuraminidase inhibitors in Japan</article-title>. <source>J Infect Chemother</source>. <year>2011</year>;<volume>17</volume>(<issue>5</issue>):<fpage>595</fpage>&#x02013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1007/s10156-011-0288-0</pub-id>
<?supplied-pmid 21850418?><pub-id pub-id-type="pmid">21850418</pub-id></mixed-citation></ref><ref id="pone.0231217.ref003"><label>3</label><mixed-citation publication-type="other">Ministry of Health, Labour and Welfare. Countermeasures for influenza epidemic of Japan (in Japanese) 2019 [<ext-link ext-link-type="uri" xlink:href="https://www.mhlw.go.jp/bunya/kenkou/influenza/">https://www.mhlw.go.jp/bunya/kenkou/influenza/</ext-link>.</mixed-citation></ref><ref id="pone.0231217.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Hayden</surname><given-names>FG</given-names></name>, <name><surname>Sugaya</surname><given-names>N</given-names></name>, <name><surname>Hirotsu</surname><given-names>N</given-names></name>, <name><surname>Lee</surname><given-names>N</given-names></name>, <name><surname>de Jong</surname><given-names>MD</given-names></name>, <name><surname>Hurt</surname><given-names>AC</given-names></name>, <etal>et al</etal>
<article-title>Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>(<issue>10</issue>):<fpage>913</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1716197</pub-id>
<?supplied-pmid 30184455?><pub-id pub-id-type="pmid">30184455</pub-id></mixed-citation></ref><ref id="pone.0231217.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Sugaya</surname><given-names>N</given-names></name>, <name><surname>Shinjoh</surname><given-names>M</given-names></name>, <name><surname>Mitamura</surname><given-names>K</given-names></name>, <name><surname>Takahashi</surname><given-names>T</given-names></name>. <article-title>Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: Analysis of 1000 hospitalized children</article-title>. <source>J Infect</source>. <year>2011</year>;<volume>63</volume>(<issue>4</issue>):<fpage>288</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2011.06.008</pub-id>
<?supplied-pmid 21722665?><pub-id pub-id-type="pmid">21722665</pub-id></mixed-citation></ref><ref id="pone.0231217.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Havers</surname><given-names>F</given-names></name>, <name><surname>Thaker</surname><given-names>S</given-names></name>, <name><surname>Clippard</surname><given-names>JR</given-names></name>, <name><surname>Jackson</surname><given-names>M</given-names></name>, <name><surname>McLean</surname><given-names>HQ</given-names></name>, <name><surname>Gaglani</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Use of Influenza Antiviral Agents by Ambulatory Care Clinicians During the 2012&#x02013;2013 Influenza Season</article-title>. <source>Clin Infect Dis</source>. <year>2014</year>;<volume>59</volume>(<issue>6</issue>): <fpage>774</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu422</pub-id>
<?supplied-pmid 25034419?><pub-id pub-id-type="pmid">25034419</pub-id></mixed-citation></ref><ref id="pone.0231217.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Benito-Fernandez</surname><given-names>J</given-names></name>, <name><surname>Vazquez-Ronco</surname><given-names>MA</given-names></name>, <name><surname>Morteruel-Aizkuren</surname><given-names>E</given-names></name>, <name><surname>Mintegui-Raso</surname><given-names>S</given-names></name>, <name><surname>Sanchez-Etxaniz</surname><given-names>J</given-names></name>, <name><surname>Fernandez-Landaluce</surname><given-names>A</given-names></name>. <article-title>Impact of rapid viral testing for influenza A and B viruses on management of febrile infants without signs of focal infection</article-title>. <source>Pediatr Dis Infect J</source>. <year>2006</year>;<volume>25</volume>(<issue>12</issue>):<fpage>1153</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0231217.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Noyola</surname><given-names>DE</given-names></name>, <name><surname>Demmler</surname><given-names>GJ</given-names></name>. <article-title>Effect of rapid diagnosis on management of influenza A infections</article-title>. <source>Pediatr Dis Infect J</source>. <year>2000</year>;<volume>19</volume>(<issue>4</issue>):<fpage>303</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0231217.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Merckx</surname><given-names>J</given-names></name>, <name><surname>Wali</surname><given-names>R</given-names></name>, <name><surname>Schiller</surname><given-names>I</given-names></name>, <name><surname>Caya</surname><given-names>C</given-names></name>, <name><surname>Gore</surname><given-names>GC</given-names></name>, <name><surname>Chartrand</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis</article-title>. <source>Ann Intern Med</source>. <year>2017</year>;<volume>167</volume>(<issue>6</issue>):<fpage>394</fpage>&#x02013;<lpage>409</lpage>. <pub-id pub-id-type="doi">10.7326/M17-0848</pub-id>
<?supplied-pmid 28869986?><pub-id pub-id-type="pmid">28869986</pub-id></mixed-citation></ref><ref id="pone.0231217.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Bruning</surname><given-names>AHL</given-names></name>, <name><surname>Leeflang</surname><given-names>MMG</given-names></name>, <name><surname>Vos</surname><given-names>J</given-names></name>, <name><surname>Spijker</surname><given-names>R</given-names></name>, <name><surname>de Jong</surname><given-names>MD</given-names></name>, <name><surname>Wolthers</surname><given-names>KC</given-names></name>, <etal>et al</etal>
<article-title>Rapid Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review and Meta-analysis</article-title>. <source>Clinical infectious diseases: an official publication of the Infectious Diseases Society of America</source>. <year>2017</year>;<volume>65</volume>(<issue>6</issue>):<fpage>1026</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">28520858</pub-id></mixed-citation></ref><ref id="pone.0231217.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Ip</surname><given-names>DKM</given-names></name>, <name><surname>Lau</surname><given-names>LLH</given-names></name>, <name><surname>Chan</surname><given-names>KH</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Leung</surname><given-names>GM</given-names></name>, <name><surname>Peiris</surname><given-names>MJS</given-names></name>, <etal>et al</etal>
<article-title>The Dynamic Relationship Between Clinical Symptomatology and Viral Shedding in Naturally Acquired Seasonal and Pandemic Influenza Virus Infections</article-title>. <source>Clin Infect Dis</source>. <year>2016</year>;<volume>62</volume>(<issue>4</issue>):<fpage>431</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ909</pub-id>
<?supplied-pmid 26518469?><pub-id pub-id-type="pmid">26518469</pub-id></mixed-citation></ref><ref id="pone.0231217.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>C</given-names></name>, <name><surname>Chaves</surname><given-names>SS</given-names></name>, <name><surname>Perez</surname><given-names>A</given-names></name>, <name><surname>D&#x02019;Mello</surname><given-names>T</given-names></name>, <name><surname>Daily Kirley</surname><given-names>P</given-names></name>, <name><surname>Aragon</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Complications among adults hospitalized with influenza: a comparison of seasonal influenza and the 2009 H1N1 pandemic</article-title>. <source>Clin Infect Dis</source>. <year>2014</year>;<volume>59</volume>(<issue>2</issue>):<fpage>166</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu285</pub-id>
<?supplied-pmid 24785230?><pub-id pub-id-type="pmid">24785230</pub-id></mixed-citation></ref><ref id="pone.0231217.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Sakai-Tagawa</surname><given-names>Y</given-names></name>, <name><surname>Yamayoshi</surname><given-names>S</given-names></name>, <name><surname>Kawakami</surname><given-names>C</given-names></name>, <name><surname>Le</surname><given-names>MQ</given-names></name>, <name><surname>Uchida</surname><given-names>Y</given-names></name>, <name><surname>Saito</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>14483</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-14536-0</pub-id>
<?supplied-pmid 29101372?><pub-id pub-id-type="pmid">29101372</pub-id></mixed-citation></ref><ref id="pone.0231217.ref014"><label>14</label><mixed-citation publication-type="other">TAUNS. ImunoAce Flu (in Japanese) 2019 [cited 2019 December 14]. Available from: <ext-link ext-link-type="uri" xlink:href="http://imunoace.jp/flu/">http://imunoace.jp/flu/</ext-link>.</mixed-citation></ref><ref id="pone.0231217.ref015"><label>15</label><mixed-citation publication-type="other">TAUNS. Linjudge FluA/pdm (in Japanese) 2019 [<ext-link ext-link-type="uri" xlink:href="http://www.tauns.co.jp/news/2010/1216.pdf#search=%27Linjudge+FluA%2Fpdm%2C+tauns%27">http://www.tauns.co.jp/news/2010/1216.pdf#search=%27Linjudge+FluA%2Fpdm%2C+tauns%27</ext-link>.</mixed-citation></ref><ref id="pone.0231217.ref016"><label>16</label><mixed-citation publication-type="other">National Institute of Infectious Diseases. Manual for the Diagnosis of Influenza Virus (in Japanese) 2018 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.niid.go.jp/niid/images/lab-manual/influenza20190116.pdf">https://www.niid.go.jp/niid/images/lab-manual/influenza20190116.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0231217.ref017"><label>17</label><mixed-citation publication-type="other">FluNet. Influenza Laboratory Information by the GISRS. 2019 [<ext-link ext-link-type="uri" xlink:href="http://apps.who.int/flumart/Default?ReportNo=1&#x00026;CountryCode=JP">http://apps.who.int/flumart/Default?ReportNo=1&#x00026;CountryCode=JP</ext-link></mixed-citation></ref><ref id="pone.0231217.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Uyeki</surname><given-names>TM</given-names></name>, <name><surname>Bernstein</surname><given-names>HH</given-names></name>, <name><surname>Bradley</surname><given-names>JS</given-names></name>, <name><surname>Englund</surname><given-names>JA</given-names></name>, <name><surname>File</surname><given-names>TM</given-names></name>, <name><surname>Fry</surname><given-names>AM</given-names></name>, <etal>et al</etal>
<article-title>Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa</article-title>. <source>Clin Infect Dis</source>. <year>2019</year>;<volume>68</volume>(<issue>6</issue>):<fpage>895</fpage>&#x02013;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy874</pub-id>
<?supplied-pmid 30834445?><pub-id pub-id-type="pmid">30834445</pub-id></mixed-citation></ref><ref id="pone.0231217.ref019"><label>19</label><mixed-citation publication-type="other">Pharmaceuticals and Medical Devices Agency. Inserts of medical diagnostic devices 2014 [updated 2014. <ext-link ext-link-type="uri" xlink:href="http://www.info.pmda.go.jp/tsearch/html/menu_tenpu_base.html">http://www.info.pmda.go.jp/tsearch/html/menu_tenpu_base.html</ext-link>.</mixed-citation></ref><ref id="pone.0231217.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>CK</given-names></name>, <name><surname>Cowling</surname><given-names>BJ</given-names></name>, <name><surname>Chan</surname><given-names>KH</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Seto</surname><given-names>WH</given-names></name>, <name><surname>Yung</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Factors affecting QuickVue Influenza A + B rapid test performance in the community setting</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>2009</year>;<volume>65</volume>(<issue>1</issue>):<fpage>35</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2009.05.003</pub-id>
<?supplied-pmid 19679233?><pub-id pub-id-type="pmid">19679233</pub-id></mixed-citation></ref><ref id="pone.0231217.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Koul</surname><given-names>PA</given-names></name>, <name><surname>Mir</surname><given-names>H</given-names></name>, <name><surname>Bhat</surname><given-names>MA</given-names></name>, <name><surname>Khan</surname><given-names>UH</given-names></name>, <name><surname>Khan</surname><given-names>MM</given-names></name>, <name><surname>Chadha</surname><given-names>MS</given-names></name>, <etal>et al</etal>
<article-title>Performance of rapid influenza diagnostic tests (QuickVue) for influenza A and B Infection in India</article-title>. <source>Indian J Med Microbiol</source>. <year>2015</year>;<volume>33</volume>
<issue>Suppl</issue>:<fpage>26</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">25657152</pub-id></mixed-citation></ref><ref id="pone.0231217.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Millman</surname><given-names>AJ</given-names></name>, <name><surname>Reed</surname><given-names>C</given-names></name>, <name><surname>Kirley</surname><given-names>PD</given-names></name>, <name><surname>Aragon</surname><given-names>D</given-names></name>, <name><surname>Meek</surname><given-names>J</given-names></name>, <name><surname>Farley</surname><given-names>MM</given-names></name>, <etal>et al</etal>
<article-title>Improving Accuracy of Influenza-Associated Hospitalization Rate Estimates</article-title>. <source>Emerg Infect Dis</source>. <year>2015</year>;<volume>21</volume>(<issue>9</issue>):<fpage>1595</fpage>&#x02013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.3201/eid2109.141665</pub-id>
<?supplied-pmid 26292017?><pub-id pub-id-type="pmid">26292017</pub-id></mixed-citation></ref><ref id="pone.0231217.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Harada</surname><given-names>D</given-names></name>, <name><surname>Nishiuchi</surname><given-names>R</given-names></name>, <name><surname>Iwasaki</surname><given-names>Y</given-names></name>, <name><surname>Watanabe</surname><given-names>H</given-names></name>, <name><surname>Tokorodani</surname><given-names>C</given-names></name>, <name><surname>Kanazawa</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Reliability of a rapid test for the clinical diagnosis of influenza A/H1N1 2009</article-title>. <source>Scand J Infect Dis</source>. <year>2012</year>;<volume>44</volume>(<issue>10</issue>):<fpage>776</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.3109/00365548.2012.686670</pub-id>
<?supplied-pmid 22803629?><pub-id pub-id-type="pmid">22803629</pub-id></mixed-citation></ref><ref id="pone.0231217.ref024"><label>24</label><mixed-citation publication-type="journal"><collab>Centers for Disease C, Prevention</collab>. <article-title>Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) Virus&#x02014;United States, 2009</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2009</year>;<volume>58</volume>(<issue>30</issue>):<fpage>826</fpage>&#x02013;<lpage>9</lpage>. <?supplied-pmid 19661856?><pub-id pub-id-type="pmid">19661856</pub-id></mixed-citation></ref><ref id="pone.0231217.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Mitamura</surname><given-names>K</given-names></name>, <name><surname>Shimizu</surname><given-names>H</given-names></name>, <name><surname>Yamazaki</surname><given-names>M</given-names></name>, <name><surname>Ichikawa</surname><given-names>M</given-names></name>, <name><surname>Abe</surname><given-names>T</given-names></name>, <name><surname>Yasumi</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Clinical evaluation of ID NOW influenza A &#x00026; B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology&#x02014;A comparison with currently available tests</article-title>. <source>J Infect Chemother</source>. <year>2019</year>.</mixed-citation></ref><ref id="pone.0231217.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Yaron-Yakoby</surname><given-names>H</given-names></name>, <name><surname>Sefty</surname><given-names>H</given-names></name>, <name><surname>Pando</surname><given-names>R</given-names></name>, <name><surname>Dichtiar</surname><given-names>R</given-names></name>, <name><surname>Katz</surname><given-names>MA</given-names></name>, <name><surname>Stein</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Effectiveness of influenza vaccine in preventing medically-attended influenza virus infection in primary care, Israel, influenza seasons 2014/15 and 2015/16</article-title>. <source>Euro Surveill</source>. <year>2018</year>;<volume>23</volume>(<issue>7</issue>).</mixed-citation></ref><ref id="pone.0231217.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>Janjua</surname><given-names>NZ</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>, <name><surname>Sabaiduc</surname><given-names>S</given-names></name>, <name><surname>Eshaghi</surname><given-names>A</given-names></name>, <name><surname>Dickinson</surname><given-names>JA</given-names></name>, <etal>et al</etal>
<article-title>Low 2012&#x02013;13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses</article-title>. <source>PloS one</source>. <year>2014</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e92153</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0092153</pub-id>
<?supplied-pmid 24667168?><pub-id pub-id-type="pmid">24667168</pub-id></mixed-citation></ref><ref id="pone.0231217.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Sugaya</surname><given-names>N</given-names></name>, <name><surname>Shinjoh</surname><given-names>M</given-names></name>, <name><surname>Kawakami</surname><given-names>C</given-names></name>, <name><surname>Yamaguchi</surname><given-names>Y</given-names></name>, <name><surname>Yoshida</surname><given-names>M</given-names></name>, <name><surname>Baba</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan</article-title>. <source>Euro Surveill</source>. <year>2016</year>;<volume>21</volume>(<issue>42</issue>).</mixed-citation></ref><ref id="pone.0231217.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Hirotsu</surname><given-names>N</given-names></name>, <name><surname>Sakaguchi</surname><given-names>H</given-names></name>, <name><surname>Sato</surname><given-names>C</given-names></name>, <name><surname>Ishibashi</surname><given-names>T</given-names></name>, <name><surname>Baba</surname><given-names>K</given-names></name>, <name><surname>Omoto</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes</article-title>. <source>Clin Infect Dis</source>. <year>2019</year>.</mixed-citation></ref><ref id="pone.0231217.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Mitamura</surname><given-names>K</given-names></name>, <name><surname>Kawakami</surname><given-names>C</given-names></name>, <name><surname>Shimizu</surname><given-names>H</given-names></name>, <name><surname>Abe</surname><given-names>T</given-names></name>, <name><surname>Konomi</surname><given-names>Y</given-names></name>, <name><surname>Yasumi</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of a new immunochromatographic assay for rapid identification of influenza A, B, and A(H1N1)2009 viruses</article-title>. <source>J Infect Chemother</source>. <year>2013</year>;<volume>19</volume>(<issue>4</issue>):<fpage>633</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s10156-012-0533-1</pub-id>
<?supplied-pmid 23254398?><pub-id pub-id-type="pmid">23254398</pub-id></mixed-citation></ref><ref id="pone.0231217.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Blyth</surname><given-names>CC</given-names></name>, <name><surname>Iredell</surname><given-names>JR</given-names></name>, <name><surname>Dwyer</surname><given-names>DE</given-names></name>. <article-title>Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans</article-title>. <source>The New England journal of medicine</source>. <year>2009</year>;<volume>361</volume>(<issue>25</issue>):<fpage>2493</fpage>
<pub-id pub-id-type="doi">10.1056/NEJMc0909049</pub-id>
<?supplied-pmid 19923563?><pub-id pub-id-type="pmid">19923563</pub-id></mixed-citation></ref></ref-list></back></article>